Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension (Q48550363)

12 February 2018

title

Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension (English)

1 reference

12 February 2018

author name string

Mark H Williams

1

1 reference

12 February 2018

Clive E Handler

2

1 reference

12 February 2018

Raza Akram

3

1 reference

12 February 2018

Colette J Smith

4

1 reference

12 February 2018

Clare Das

5

1 reference

12 February 2018

Joanna Smee

6

1 reference

12 February 2018

Devaki Nair

7

1 reference

12 February 2018

Christopher P Denton

8

1 reference

12 February 2018

Carol M Black

9

1 reference

12 February 2018

John G Coghlan

10

1 reference

12 February 2018

publication date

27 April 2006

1 reference

12 February 2018

published in

European Heart Journal

1 reference

12 February 2018

volume

27

1 reference

12 February 2018

issue

12

1 reference

12 February 2018

page(s)

1485-1494

1 reference

12 February 2018

Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach

cites work

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI891

Clinical classification of pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI891

Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI891

Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI891

Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI891

B-type natriuretic peptide in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI891

Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI891

Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI891

Clinical significance of brain natriuretic peptide in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI891

Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI891

Secretion patterns of brain natriuretic peptide and atrial natriuretic peptide in patients with or without pulmonary hypertension complicating atrial septal defect

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI891

Pro-brain natriuretic peptide as marker of cardiovascular or pulmonary causes of dyspnea in patients with terminal parenchymal lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI891

Plasma brain natriuretic peptide as a noninvasive marker for efficacy of pulmonary thromboendarterectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI891

Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI891

Preliminary criteria for the classification of systemic sclerosis (scleroderma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI891

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI891

Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI891

Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI891

Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI891

Dexamethasone-induced Up-regulation of Adrenomedullin and Atrial Natriuretic Peptide Genes in Cultured Rat Ventricular Myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI891

Measurement and importance of plasma brain natriuretic peptide and related peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI891

Signal transduction by guanylyl cyclases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI891

The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI891

Skeletal overgrowth in transgenic mice that overexpress brain natriuretic peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI891

Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI891

Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI891

Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHI891

21 January 2018

Identifiers

DOI

10.1093/EURHEARTJ/EHI891

1 reference

12 February 2018

1 reference

12 February 2018